Mega Guidance Is Here!
|
|
- Barnard Fox
- 8 years ago
- Views:
Transcription
1 Mega Guidance Is Here! David Pointer has no actual or potential conflict of interest in relation to this presentation. 1
2 Introduction Where are we today? Brief Overview of HRSA Audit Findings Where are we going? Mega-Guidance 340B Program is administered by Health Resources and Service Administration (HRSA) Drug manufacturers who participate in Medicaid/Medicare are required to supply covered outpatient drugs to covered entities at discounted prices Program funded by manufacturers, not Medicare or taxpayers The intent of the 340B program is to stretch scarce federal resources to reach a greater number of eligible patients and provide comprehensive services. Intent is not to save patients money 2
3 340B Program began in 1992, contract pharmacies became eligible in 1996, DSH expansion occurred in 2003, children s hospitals were added in 2006 and critical access hospitals were included in B Volume by Type** Pre 2004 DSH 31% Post 2004 DSH 50% HIV 5% SCH 2% CAH 2% 340B Purchase Volume (Billion)* 2005 $ $ $7.1 Projected 2019 $16 Other 10% * Per Apexus ** Per Berkeley Research Group 3
4 No findings 42% 21% 19% 26% Findings 58% 79% 81% 74% Repayment 45% 63% 65% 57% State repaid 3% 1% Per 340B Health Diversion 33% 58% 60% 42% Duplicate discount 30% 21% 21% 20% Inaccurate database 24% 49% 47% 44% Contract pharmacy oversight 4% 5% 3% GPO 1% 11% 6% Inauditable records 1% Non-reimbursable site 1% 1% DSH % 1% Inaccurate Medicaid Exclusion File 2% Orphan drug violation 5% Per 340B Health 4
5 May 6, 2015 HRSA submits Mega-Guidance to the Office of Management and Budget (OMB) August 28, 2015 Proposed Mega-Guidance is released in Federal Register October 27, 2015 Deadline to submit comments on proposed guidance ends (60 days) Unknown HRSA finalizes Mega-Guidance 5
6 Mega-Guidance Purpose Provide increased clarity for stakeholders and strengthen HRSA s ability to administer the program effectively Guidance vs. Rulemaking Proposed vs. Finalized No scripts/orders written outside hospital or child sites Infusion orders Referrals, follow-up care, affiliated clinics, non-reimbursable hospital clinics, providers treating patients outside the hospital No 340B for scripts/orders written by providers who are not employees or independent contractors where hospital bills for professional fees New focus on payer status of patient No discharge scripts No drugs given to outpatients later billed as part of inpatient stay No 340B for Medicaid bundled drugs 6
7 Patient eligibility Covered entity eligibility Covered outpatient drug definition/eligibility Covered entity responsibility Contract pharmacy Internal and external audits GPO Prohibition Existing requirements for hospitals The covered entity has established a relationship with the individual, such that the covered entity maintains records of the individual s health care; and The individual receives health care services from a health care professional who is either employed by the covered entity or provides health care under contractual or other arrangements (e.g., referral for consultation) such that responsibility for the care provided remains with the covered entity An individual will not be considered a patient of the covered entity for purposes of 340B if the only health care service received by the individual from the covered entity is the dispensing of a drug or drugs for subsequent self-administration or administration in the home setting. (61 Fed. Reg (October 24, 1996)) Per 340B Health 7
8 1. The individual receives a health care service at a facility or clinic site which is registered for the 340B Program and listed on the public 340B database 2. The individual receives a health care service provided by a covered entity provider who is either employed by the covered entity or who is an independent contractor for the covered entity such that the covered entity may bill for services on behalf of the provider 3. An individual receives a drug that is ordered or prescribed by the covered entity provider as a result of the service described in (2) 4. The individual s health care is consistent with the scope of the Federal grant, project, designation or contract 5. The individual s drug is ordered or prescribed pursuant to a health care service that is classified as outpatient 6. The individual s patient records are accessible to the covered entity and demonstrate that the covered entity is responsible for care Proposed guidance: For 340B to be used, script/order must be written as a result of a healthcare service billed as outpatient Observations: Negates discharge scripts No 340B for drugs billed as an inpatient service, even though the patient was an outpatient at the time the drug was dispensed/administered (e.g., Medicare 72-hour rule) Huge operational impact 8
9 Proposed guidance would prohibit use of 340B to fill scripts/orders written outside the hospital Patient eligible for 340B on a script-by-script basis instead of a patient-by-patient basis May not impact all facilities Proposed guidance: Order must be written as a result of services provided in the hospital or a child site to be filled with 340B drugs Mere infusion of drug not enough Observations: Hospitals have overturned audit findings by showing that even though an order was written outside the hospital, administration of the order at the hospital or a registered clinic qualified as an actual health care service for 340B purposes Proposed change would prohibit 340B use for these orders 9
10 Proposed guidance: No 340B for referrals, follow-up care or care in unregistered affiliated clinics Observations: HRSA audits have allowed in limited situations Difficult to document May not significantly impact many facilities Proposed guidance: No 340B for scripts/orders written outside registered hospital and child sites Observations: May impact treatment at: Nursing homes Correctional facilities Indigent clinics School clinics 10
11 The legal argument: Hospitals using a self-insured plan are responsible for care given to employees covered by plan HRSA audits have said this relationship is not sufficient for 340B use; not recommended currently Proposed guidance would unequivocally prohibit this Current: Employed, contracted or under other arrangement Proposed: Either employed by, or an independent contractor for, the hospital Such that the covered entity may bill for services on behalf of the provider Note: Simply having privileges or credentials is not sufficient Is more required than provider being on premises of hospital? Creates operational burdens to track and distinguish Interpreting may bill for services on behalf of the provider Hospital does bill or could bill? 11
12 Current: A drug is eligible for 340B if it is a covered outpatient drug, as defined in section 1927(k) of the Social Security Act Proposed guidance: For the 340B program, a drug will not be considered a covered outpatient drug if the drug: (1) is provided as part of, or as incident to and in the same setting as the following services: inpatient hospital services; hospice services; dental services, except that drugs for which the State plan authorizes direct reimbursement to the dispensing dentist are covered outpatient drugs; physicians services; outpatient hospital services; nursing facility services and services provided by an intermediate care facility for the mental retarded; other laboratory and x-ray services; and renal dialysis; and (2) receives a bundled payment by Medicaid and does not receive direct reimbursement for the drug. Not entirely clear what is intended: Different than current bundled drug policy May not impact all states similarly 12
13 Proposed guidance: A hospital must notify HRSA if it is no longer eligible or has violated a 340B program requirement Implications: No materiality standard Current statement used in recertification: Entities must contact HRSA if there is any material change in 340B eligibility and/or material breach of key program requirements Most hospitals currently correct minor errors without notifying HRSA This could be a regular notification for many facilities GPO prohibition only applies to DSH and free-standing children s and cancer hospitals Does not apply to CAH, RRC or SCH Proposed guidance lists three exceptions: 1. GPO could be used in clinics that: Have a different physical address Are not registered in 340B Ensure GPO drugs are never provided to outpatients at hospital or child sites Purchase drugs through a wholesale account separate from parent entity 2. GPO could be used for drugs given to an inpatient when insurer subsequently classifies as an outpatient 3. GPO could be used when 340B and WAC pricing are unavailable Hospitals may use remaining GPO drugs after start date in 340B 13
14 Proposed guidance continues to prohibit GPO use for ineligible outpatients Would also prohibit GPO use for drugs that are difficult to track (e.g., IV solutions, contrast media, anesthesia) unless paid in bundled manner by Medicaid FAQ allowed hospitals to interpret the definition of covered outpatient to decide if bundled drugs meet this definition, and if not, a GPO may be used for drugs that are not covered outpatient drugs. Some hospitals have identified certain drugs they believe are outside of 340B based on this FAQ Would need to use WAC for such drugs if hospital can t track 340B and GPO use Proposed guidance: All child sites must be listed in the contract Only covered entities may register contract pharmacies Makes clear that CEs are responsible for contract pharmacy oversight and preventing diversion and duplicate discounts CEs must conduct annual independent audits CE must conduct a quarterly review of each contract pharmacy location (e.g., comparing CE s prescribing records with pharmacy s dispensing records) CE must notify HRSA of any noncompliance found during a quarterly review or annual independent audit 14
15 Proposed guidance: CE cannot use contract pharmacy to dispense 340B drugs to Medicaid FFS or MCO patients without HRSA-approved written agreement with state or MCO Seeking alternatives to filed cost report test Could greatly shorten timeline for new child sites GPO Prohibition Confirms ability to exclude some off-site locations from 340B (and GPO prohibition) Confirms ability to use existing GPO inventory Allows different carve-in and carve-out decisions for Medicaid fee-for-service and Medicaid managed care Consideration of permitting CEs to use 340B only if appropriate for service delivery (e.g., could use non-340b account if more appropriate for a specific service, instead of carving-in or carving-out by Medicaid billing number) Does clarify some existing rules Tightened audit standards 15
16 David Pointer, President SolutionsRx P.O. Box 212 Gainesville, Missouri (417)
Mega Guidance Is Here!
Mega Guidance Is Here! David Pointer has no actual or potential conflict of interest in relation to this presentation. Introduction Where are we today? Brief Overview of HRSA Audit Findings Where are we
More informationFinally... maybe? The Long Awaited 340B Mega Guidance. Georgia Healthcare Financial Management Association. October 2015
Finally... maybe? The Long Awaited 340B Mega Guidance Georgia Healthcare Financial Management Association October 2015 Disclaimer This webinar assumes the participant is familiar with the basic operations
More informationCPAs and ADVISORS. experience access // 340B QUALIFICATIONS, BENEFITS AND CURRENT FOCUS
CPAs and ADVISORS experience access // 340B QUALIFICATIONS, BENEFITS AND CURRENT FOCUS BRIAN M. BELL BRAD K. BROTHERTON DIRECTOR PARTNER MATERIALS COVERED TODAY 340B Program Evolution, Purpose & Benefits
More information340B Drug Discount Program Improving Compliance to Protect Savings and Be Audit Ready. Suzanne Herzog Founding Director Rx X Consulting
340B Drug Discount Program Improving Compliance to Protect Savings and Be Audit Ready Suzanne Herzog Founding Director Rx X Consulting What is 340B? 340B Overview A drug discount program that allows covered
More information340B Drug Pricing Program: Recent Developments and Compliance Update
340B Drug Pricing Program: Recent Developments and Compliance Update Elizabeth S. Elson, Esq. Anil Shankar, Esq. November 19, 2015 Attorney Advertising Prior results do not guarantee a similar outcome
More information340B Mega Guidance: Implications for Essential Hospitals Sarah Mutinsky and Barbara Eyman Washington Counsel, America s Essential Hospitals Eyman
340B Mega Guidance: Implications for Essential Hospitals Sarah Mutinsky and Barbara Eyman Washington Counsel, America s Essential Hospitals Eyman Associates September 10, 2015 TODAY S AGENDA Background
More informationA fter much-anticipation, the Health Resources and
BNA s Health Care Policy Report Reproduced with permission from BNA s Health Care Policy Report, 23 HCPR 1420, 09/21/2015. Copyright 2015 by The Bureau of National Affairs, Inc. (800-372-1033) http://www.bna.com
More informationO n Aug. 28, the Department of Health and Human
BNA s Health Law Reporter Reproduced with permission from BNA s Health Law Reporter, 24 HLR 1202, 9/17/15. Copyright 2015 by The Bureau of National Affairs, Inc. (800-372-1033) http://www.bna.com HRSA
More informationLegal Alert. Long-Awaited 340B Program Guidance Now Available for Comments: What Stakeholders Need to Know. Authors
September 10, 2015 1 Legal Alert Authors Stephanie Trunk Partner stephanie.trunk@arentfox.com Erin E. Atkins Associate erin.atkins@arentfox.com Long-Awaited 340B Program Guidance Now Available for Comments:
More informationASHP Regulatory Alert
Proposed Guidance: 340B Drug Discount Program Introduction On Friday, August 28, 2015, the Health Resources and Services Administration (HRSA) published the long awaited proposed omnibus guidance for the
More information10/1/2013. Objectives. 340B Drug Pricing Program; Transitioning from Access to Integrity. 340B Stats, Arkansas. 340B Participating Entities, AR
Objectives Drug Pricing Program; Transitioning from Access to Integrity Arkansas Association of Health-system Pharmacists 47 th Annual Fall Seminar October 3 & 4, 2013 Chris Hatwig RPh, MS, FASHP President,
More informationThe 3 Keys to Success in Your 340B Program. Rob Nahoopii, PharmD, MS, BCPS CEO Turnkey Pharmacy Solutions A 340B Management Company
The 3 Keys to Success in Your 340B Program Rob Nahoopii, PharmD, MS, BCPS CEO Turnkey Pharmacy Solutions A 340B Management Company Objectives Provide a description and overview of the 340B program Discuss
More information340B Drug Pricing Program: Overview and Recent Developments
340B Drug Pricing Program: Overview and Recent Developments November 12, 2015 Kirstin B. Ives Partner and Chair of Healthcare Litigation Group Williams Montgomery & John Ltd. 233 S. Wacker Drive, Suite
More information340B Drug Discount Program Overview and Emerging Issues
340B Drug Discount Program Overview and Emerging Issues I. APPLICABLE STATUTE AND OTHER LEGAL AUTHORITIES Section 340B of the Public Health Service Act (42 U.S.C. 256b) requires pharmaceutical manufacturers,
More information340B Drug Pricing Program
340B Drug Pricing Program Chad E. Gay Director of Contract Compliance Agenda Discuss the 340B drug pricing program How the program is defined Who is eligible Enrollment Dates to be aware of Source Documentation
More informationXXXXXXXFUNDAMENTALS An Essential Guide for Health System Executive Management
340B XXXXXXXFUNDAMENTALS An Essential Guide for Health System Executive Management 800.473.3516 www.wellpartner.com Table of Contents 340B Fundamentals for Health System Executive Management...1 What
More informationFederal 340B Drug Pricing Program
2015 CliftonLarsonAllen LLP Federal 340B Drug Pricing Program March 6, 2015 Continuous learning in action Learning Objectives Explain the intent of the Federal 340B Drug Pricing Program List the eligibility
More informationOctober 9, 2015. RIN 0906-AB08 340B Drug Pricing Program Omnibus Guidance. Dear Director Pedley:
October 9, 2015 Krista Pedley Director, Office of Pharmacy Affairs Health Resources and Services Administration 5600 Fishers Lane Mail Stop 08W05A Rockville, Maryland 20857 Re: RIN 0906-AB08 340B Drug
More informationKeep Your Savings: 340B Audits and Ensuring Compliance
Keep Your Savings: 340B Audits and Ensuring Compliance Disclosure This presentation reflects experience with the topics at hand and does not constitute legal advice, and does not reflect interpretation
More informationThe 340B Program: New Developments and New Opportunities for CAHs and Others. Todd Nova Hall Render
The 340B Program: New Developments and New Opportunities for CAHs and Others Todd Nova Hall Render Wisconsin Office of Rural Health Hospital Finance Workshop August 30, 2011 What We Will Cover 2 340B Program
More information340B Drug Discount Program Identifying risks and internal audit focus areas
340B Drug Discount Program Identifying risks and internal audit focus areas Introduction The 340B Drug Discount Program is administered by the Health Resources and Services Administration (HRSA) Office
More informationSUMMARY OF HRSA PROPOSED OMNIBUS GUIDANCE ON THE 340B DRUG DISCOUNT PROGRAM
L A W O F F I C E S HYMAN, PHELPS & MCNAMARA, P.C. 7 0 0 T H I R T E E N T H S T R E E T, N. W. S U I T E 1 2 0 0 W A S H I N G T O N, D. C. 2 0 0 0 5-5 9 2 9 ( 2 0 2 ) 7 3 7-5 6 0 0 F A C S I M I L E
More informationThe 340B Drug Discount Program Overview, Compliance Issues and Interplay with Medicare and Medicaid
The Drug Discount Program Overview, Compliance Issues and Interplay with Medicare and Medicaid Barbara Straub Williams Powers Pyles Sutter & Verville PC American Health Lawyers Association 2014 Institute
More information340B DRUG DISCOUNT PROGRAM OMNIBUS GUIDANCE. Presented by the American Bar Association Health Law Section and Center for Professional Development
340B DRUG DISCOUNT PROGRAM OMNIBUS GUIDANCE Presented by the American Bar Association Health Law Section and Center for Professional Development American Bar Association Center for Professional Development
More informationSUMMARY: The Health Resources and Services Administration (HRSA) administers section
This document is scheduled to be published in the Federal Register on 08/28/2015 and available online at http://federalregister.gov/a/2015-21246, and on FDsys.gov Billing Code: 4165-15 DEPARTMENT OF HEALTH
More information340B Compliance: I sure wish I d known that!
340B Compliance: I sure wish I d known that! Aaron K. Lott Pharm. D. Executive Director of Pharmacy Services June 2015 Disclosures The presenter has no significant financial or commercial interests to
More informationNAMD WORKING PAPER SERIES. Medicaid and the 340B Program: Alignment and Modernization Opportunities
NAMD WORKING PAPER SERIES Medicaid and the 340B Program: Alignment and Modernization Opportunities May 2015 444 North Capitol Street, Suite 524 Washington, DC 20001 Phone: 202.403.8620 www.medicaiddirectors.org
More information340B Policy Landscape
340B Policy Landscape Providence 2015 340B Summit Presented by Steve Brennan, Director, Public Policy Providence Health & Services Sept. 28, 2015 1 Today s topics Backdrop of debate over 340B program Legislative
More information340B Omnibus Guidance Would Significantly Narrow the Pool of Eligible Patients
White Paper August 31, 2015 340B Omnibus Guidance Would Significantly Narrow the Pool of Eligible Patients By Kristi V. Kung This client alert also was published as a bylined article on Law360 on September
More information(RIN) 0906-AB08; 340-B
October, 2015 Ms. Krista Pedley Director, Office of Pharmacy Affairs (OPA) Health Resources and Services Administration (HRSA) 5600 Fishers Lane, Mail Stop 08W05A Rockville, Maryland 20857 Re: Regulatory
More information4/3/2015 WHAT IS 340B? DISCLOSURE. No conflicts of interest to disclose
WHAT IS 340B? S C O T T M I L N E R P H AR M D, M B A DISCLOSURE No conflicts of interest to disclose 1 OBJECTIVES At the end of this presentation we should be able to: Describe the origin of the 340b
More informationThe 340B Drug Pricing Program. Ariel Winter and Daniel Zabinski November 6, 2014
The 340B Drug Pricing Program Ariel Winter and Daniel Zabinski November 6, 2014 Outline Background on 340B program Program has grown substantially 340B statute does not define key terms, allows many providers
More information340B: ARE WE MONITORING COMPLIANCE EFFECTIVELY AND EFFICIENTLY
CPAs & ADVISORS experience clarity // 340B: ARE WE MONITORING COMPLIANCE EFFECTIVELY AND EFFICIENTLY September 17, 2014 Michael Earls, CPA, Senior Manager September 17, 2014 OVERVIEW OF TODAY S PRESENTATION
More information340B PROGRAM. Scrutiny & Uncertainty Increase the Need for Compliance
340B PROGRAM Scrutiny & Uncertainty Increase the Need for Compliance Uncertainty will always be part of the taking charge process. Harold S. Geneen For many years, drug manufacturers and Covered Entities
More informationHHS Releases Long-Awaited 340B Proposed Guidance
AUGUST 31, 2015 HHS Releases Long-Awaited 340B Proposed Guidance David Ivill, Emily Cook and Joseph Parise On August 27, 2015, the U.S. Department of Health and Human Services (HHS) released the long-awaited
More informationOctober 27, 2015. Attention: RIN 0906-AB08. RE: 340B Drug Pricing Program Omnibus Guidance. Dear Captain Pedley:
Captain Krista Pedley, Director Office of Pharmacy Affairs Health Resources and Services Administration 5600 Fishers Lane Mail Stop 08W05A Rockville, MD 20857 Attention: RIN 0906-AB08 RE: 340B Drug Pricing
More informationHRSA Issues 340B Program Omnibus Guidance
3 September 2015 Practice Groups: Healthcare FDA HRSA Issues 340B Program Omnibus Guidance By Gina L. Bertolini, Richard P. Church, Leah D'Aurora Richardson On August 28, 2015, the Health Resources and
More information340B University Page 1 Split-Billing Software Considerations Checklist
340B University Page 1 Purpose: The purpose of this tool is to provide a decision checklist for entities to evaluate split-billing software. The tool presents considerations for an entity when selecting,
More information340B Drug Pricing Program. A Survey of the Program s Past, Present, and Future
340B Drug Pricing Program A Survey of the Program s Past, Present, and Future Presented by: Daniel Soldato Wyatt, Tarrant & Combs LLP dsoldato@wyattfirm.com (859) 288-7631 Disclaimer The views expressed
More informationSpeakers. Recent Developments in 340B Drug Pricing Program Compliance and Enforcement. Elizabeth S. Elson, Esq. Anil Shankar, Esq.
1 Recent Developments in 340B Drug Pricing Program Compliance and Enforcement Elizabeth S. Elson, Esq. Anil Shankar, Esq. October 18, 2012 2 Speakers Elizabeth Elson Of Counsel Foley & Lardner LLP Los
More information340B Compliance Self-Assessment: Self-Audit Process Page 1 A Sample Self-Audit Process for Community Health Centers
340B Compliance Self-Assessment: Self-Audit Process Page 1 Purpose: The purpose of this tool is to provide a sample internal audit process to assist participating community health center (CHC) leaders
More informationStructuring 340B Contract Pharmacy Arrangements: Meeting Legal and Regulatory Requirements
Presenting a live 90-minute webinar with interactive Q&A Structuring 340B Contract Pharmacy Arrangements: Meeting Legal and Regulatory Requirements THURSDAY, JUNE 4, 2015 1pm Eastern 12pm Central 11am
More information340B Integrity Audit: Is Your Hospital Ready for a HRSA Audit? February 4, 2013
340B Integrity Audit: Is Your Hospital Ready for a HRSA Audit? February 4, 2013 1 Agenda 340B Program Overview Why HRSA Audits? What will HRSA Audits Cover? Verification of Eligibility: Covered Entity,
More information2015-340B & Prime Vendor Program Update
2015-340B & Prime Vendor Program Update Christopher A. Hatwig, R.Ph., MS, FASHP President, Apexus 340B Sales by Entity Types Percentage of Total Apexus Participant Sales 90.00% 80.00% 70.00% 60.00% 50.00%
More information340B Drug Discount Program 2013 March 15, 2013 1 Agenda 340B Program Overview Covered Entities Covered Drugs Covered Patients Why HRSA Audits How to Prepare for HRSA Audit Questions/Answers 2 340 DRUG
More information340B Drug Pricing Program January 15, 2015
340B Drug Pricing Program January 15, 2015 340B Basics - Gary Merchant. MBA, BSPharm 340B Audit - Robert Theriault, MBA, BSPharm Declarations Neither Gary Merchant nor Robert Theriault have no actual or
More informationDisclosure. Overview. Safety Net Hospitals for Pharmaceutical Access
340B: Issues and Opportunities in Pharmacy Automation Safety Net Hospitals for Pharmaceutical Access Executive Director, SNHPA Editor in Chief, Drug Discount Monitor American Society for Automation in
More informationExpanding 340B Participation: The Provider-Based Challenge
Expanding 340B Participation: The Provider-Based Challenge Presentation by Karen Smith, Esq. & David Johnston, Esq. Bricker & Eckler LLP www.bricker.com Columbus l Cleveland l Cincinnati-Dayton I Marietta
More informationOctober 27, 2015. Krista Pedley, Director Office of Pharmacy Affairs Health Resources and Services Administration.
1015 15 th Street, N.W., Suite 950 Washington, DC 20005 Tel. 202.204.7508 Fax 202.204.7517 www.communityplans.net John Lovelace, Chairman Margaret A. Murray, Chief Executive Officer October 27, 2015 Krista
More informationHRSA Issues Proposed Omnibus 340B Guidance
HRSA Issues Proposed Omnibus 340B Guidance September 2015 1 HRSA Issues Proposed Omnibus 340B Guidance John Gould, Jeffrey L. Handwerker, Rosemary Maxwell, Matthew T. Fornataro, Kristin M. Hicks, Rahul
More informationOverview of the 340B Drug Pricing Program
M a y 2 0 1 5 Report to the Congress Overview of the 340B Drug Pricing Program M a y 2 0 1 5 Report to the Congress Overview of the 340B Drug Pricing Program 425 I Street, NW Suite 701 Washington, DC 20001
More informationVia Electronic Submission at http://www.regulations.gov. October 27, 2015
Via Electronic Submission at http://www.regulations.gov October 27, 2015 Krista Pedley, PharmD, MS Captain, United States Public Health Service Director, Office of Pharmacy Affairs Health Resources and
More informationOPA DATABASE GUIDE PUBLIC USERS - RECERTIFICATION FOR AUGUST 2013 VERSION 5.2.1
OPA DATABASE GUIDE FOR PUBLIC USERS - RECERTIFICATION AUGUST 2013 VERSION 5.2.1 CERTIFICATION 1 Authorizing Official (AO) Advance Notification 1 340B Recertification Email 2 AO Logging In 3 Navigating
More information340B Drug Pricing Program 340B Contract Pharmacy
340B Drug Pricing Program 340B Contract Pharmacy LTJG Enudio Mercado-Gonzalez, USPHS Program Management Officer U.S. Department of Health and Human Services Health Resources and Services Administration
More informationMEDICARE PART B DRUGS. Action Needed to Reduce Financial Incentives to Prescribe 340B Drugs at Participating Hospitals
United States Government Accountability Office Report to Congressional Requesters June 2015 MEDICARE PART B DRUGS Action Needed to Reduce Financial Incentives to Prescribe 340B Drugs at Participating Hospitals
More informationDEPARTMENT OF HEALTH AND HUMAN SERVICES Health Resources and Services Administration RIN 0906-AB08 340B Drug Pricing Program Omnibus Guidance
Page 1 THOT Members AUSTIN Central Health Seton Healthcare Family CORPUS CHRISTI CHRISTUS Spohn Health System Nueces County Hospital District DALLAS Children s Health System of Texas Parkland Health &
More informationOctober 26, 2015. Submitted electronically via http://www.regulations.gov. Re: RIN 0906-AB08; 340B Drug Pricing Program Omnibus Guidance
20555 Victor Parkway Livonia, MI 48152 tel 734-343-1000 trinity-health.org October 26, 2015 Captain Krista Pedley, PharmD, MS Director Office of Pharmacy Affairs Health Resources and Services Administration
More informationC. Covered 340B drugs, as found in section 1927 (k)(2) of the Social Security Act, include the following outpatient drugs:
Title 23: Medicaid Part 200: General Provider Information Part 200 Chapter 4: Provider Enrollment Rule 4.10: 340B Providers A. The Division of Medicaid defines a 340B provider as a nonprofit healthcare
More informationRE: 340B Drug Pricing Program Omnibus Guidance HRSA RIN 0906-AB08, (Vol. 80, No. 167, August 28, 2015)
October 26, 2015 Krista Pedley, PharmD, MS Captain, USPHS Director, Office of Pharmacy Affairs Health Resources and Services Administration 5600 Fishers Lane, Mail Stop 08W05A Rockville, MD 20857 Via Email:
More information340B Program New Developments and Increasing Scrutiny
340B Program New Developments and Increasing Scrutiny Todd Nova Hall Render tnova@hallrender.com Wisconsin Office of Rural Health Hospital Finance Workshop August 24, 2012 What We Will Cover 2 340B Program
More informationGAO DRUG PRICING. Manufacturer Discounts in the 340B Program Offer Benefits, but Federal Oversight Needs Improvement
GAO United States Government Accountability Office Report to Congressional Committees September 2011 DRUG PRICING Manufacturer Discounts in the 340B Program Offer Benefits, but Federal Oversight Needs
More informationDSH Litigation and 340B Program Update: What Participating Hospitals Need to Know and What They Should Be Doing
DSH Litigation and 340B Program Update: What Participating Hospitals Need to Know and What They Should Be Doing Presented by: Joe Metro, Partner Sal Rotella, Partner Agenda Disproportionate Share Hospital
More informationHRSA Publishes 340B Drug Pricing Program Omnibus Guidance Notice: Significant Policy Ramifications Should Trigger Public Comment
Alert Life Sciences Health Industry If you have questions or would like additional information on the material covered in this Alert, please contact one of the attorneys listed below: Joseph W. Metro Partner,
More informationPrescription drugs are a critical component of health care. Because of the role of drugs in treating conditions, it is important that Medicare ensures that its beneficiaries have access to appropriate
More informationThe Pharmacy 340B Program- Compliance & Internal Audit Strategies. for Covered Entities. Matthew D. Vogelien Huron Healthcare
The Pharmacy 340B Program- Compliance & Internal Audit Strategies Matthew D. Vogelien Huron Healthcare for Covered Entities 340B Drug Discount Program (340B Program) Discussion Outline Topics for Discussion:
More informationIs your organization 340B equipped? Understanding Contract Pharmacy arrangements
Is your organization 340B equipped? Understanding Contract Pharmacy arrangements In today s era of healthcare reform that emphasizes enhanced accessibility and cost reductions, the 340B program remains
More informationEnsuring Integrity in use of 340B pricing: Responsibility, Compliance, Accountability
Ensuring Integrity in use of 340B pricing: Responsibility, Compliance, Accountability Fern Paul-Aviles, PharmD, MS, BCPS Director, 340B and Ambulatory Regulatory Program Compliance Carolinas Healthcare
More informationThe 340B Program: Today and Beyond
FL Regional Education Session - Tampa The 340B Program: Today and Beyond May 19, 2015 2:15-3:15 PM ET 2015 Safety Net Hospitals for Pharmaceutical Access 1 Disclaimer This presentation is not to be construed
More informationGROWTH OF THE 340B PROGRAM: PAST TRENDS, FUTURE PROJECTIONS
: PAST TRENDS, FUTURE PROJECTIONS Healthcare WHITE PAPER NOVEMBER 2014 Prepared By: Aaron Vandervelde avandervelde@thinkbrg.com 202.480.2661 Copyright 2014 by Berkeley Research Group, LLC. Except as may
More information7/16/2010. 14 th Annual 340B Coalition Conference July 19, 2010 Washington, DC. Safety Net Hospitals for Pharmaceutical Access
Safety Net Hospitals for Pharmaceutical Access The Story From Washington, D.C. Ted Slafsky Executive Director, SNHPA Editor in Chief, Drug Discount Monitor (202)552-58605860 ted.slafsky@snhpa.org 14 th
More informationMaximizing the 340B Drug Discount Program: A Webinar for Finance Executives in 340B Hospitals Webinar
Maximizing the 340B Drug Discount Program: A Webinar for Finance Executives in 340B Hospitals Webinar January 20, 2010 The Webinar Will Begin Momentarily National Association of Public Hospitals and Health
More informationJuly 27, 2015. Dear Acting Administrator Slavitt:
Acting Administrator Centers for Medicare & Medicaid Services Department of Health and Human Services Attention: CMS-2390-P P.O. Box 8106 Baltimore, MD 21244-8016 Re: Proposed Rule for Medicaid and Children
More informationMedicaid and 340B. Presentation to: GHA 340B Day Presented by: Linda Wiant, Pharm.D. Pharmacy Director. Date: 10-23-14 0
Medicaid and 340B Presentation to: GHA 340B Day Presented by: Linda Wiant, Pharm.D. Pharmacy Director Date: 10-23-14 0 Mission The Georgia Department of Community Health We will provide Georgians with
More informationHRSA Pharmacy Services Support Center: The 340B Access Resource
HRSA Pharmacy Services Support Center: The 340B Access Resource Lisa Scholz PharmD, MBA Vice President, APhA HRSA Pharmacy Services Support Center Office of Population Affairs Webinar 9/16 INTEGRITY ACCESS
More informationTEXAS VENDOR DRUG PROGRAM PHARMACY PROVIDER PROCEDURE MANUAL
1 OF 10 DOCUMENT HISTORY LOG STATUS REVISION EFFECTIVE DESCRIPTION Revision 1.1 Sep. 1, 2015 Baseline 1.0 Feb. 1, 2015 3.1 Eligible Entity 5 CAD Claim Submission o Instruction update and email address.
More information340B GROWTH AND THE IMPACT ON THE ONCOLOGY MARKETPLACE
340B GROWTH AND THE IMPACT ON THE ONCOLOGY MARKETPLACE Healthcare WHITE PAPER SEPTEMBER 2015 Prepared By: Aaron Vandervelde avanvervelde@thinkbrg.com 202.480.2661 Copyright 2015 by Berkeley Research Group,
More informationOIG Responses to Additional Questions from Chairman Pitts Regarding the 340B Program May 4, 2015
OIG Responses to Additional Questions from Chairman Pitts Regarding the 340B Program May 4, 2015 1. HRSA had been preparing a regulation to address the definition of a patient and hospital eligibility,
More informationAHLA. Transmitting PHI by Email (page 16) 340B Program Covered Entity Audits (page 24) FCA Cases Involving Swapping Schemes (page 42)
AHLA March 2014 Volume 18 Issue 3 For the health and life sciences law community Transmitting PHI by Email (page 16) 340B Program Covered Entity Audits (page 24) FCA Cases Involving Swapping Schemes (page
More informationThe 340B Drug Pricing Program: The Basics
The 340B Drug Pricing Program: The Basics Paul Shank, MBA Health & Human Services Consultant, Health Resources and Services Administration Healthcare Systems Bureau, Office of Pharmacy Affairs July 14,
More informationMaryland Medicaid Program: An Overview. Stacey Davis Planning Administration Department of Health and Mental Hygiene May 22, 2007
Maryland Medicaid Program: An Overview Stacey Davis Planning Administration Department of Health and Mental Hygiene May 22, 2007 1 Maryland Medicaid In Maryland, Medicaid is also called Medical Assistance
More information340B DISCOUNT DRUG PROGRAM OVERVIEW
340B DISCOUNT DRUG PROGRAM OVERVIEW March 2014 Investment banking services are provided by Harris Williams LLC, a registered broker-dealer and member of FINRA and SIPC, and Harris Williams & Co. Ltd, which
More informationRegulatory Compliance Policy No. COMP-RCC 4.07 Title:
I. SCOPE: Regulatory Compliance Policy No. COMP-RCC 4.07 Page: 1 of 7 This policy applies to (1) any Hospital in which Tenet Healthcare Corporation or an affiliate owns a direct or indirect equity interest
More information340B UNIVERSITY San Francisco Edition. February 3-4, 2015
340B UNIVERSITY San Francisco Edition February 3-4, 2015 WELCOME TO 340B UNIVERSITY! About Apexus The mission of Apexus is to leverage our unique resources and expertise to deliver maximum value to 340B
More informationSec. 340B PUBLIC HEALTH SERVICE ACT
Sec. 340B PUBLIC HEALTH SERVICE ACT LIMITATION ON PRICES OF DRUGS PURCHASED BY COVERED ENTITIES (a) REQUIREMENTS FOR AGREEMENT WITH SECRETARY. (1) IN GENERAL. The Secretary shall enter into an agreement
More information340B Drug Pricing Program Results of a Survey of Eligible but Non-Participating Rural Hospitals
340B Drug Pricing Program Results of a Survey of Eligible but Non-Participating Rural Hospitals A Joint Publication of The North Carolina Rural Health Research & Policy Analysis Center (1) Working Paper
More informationOctober 27, 2015. Re: Comments on HRSA Notice 340B Drug Pricing Program Omnibus Guidance (RIN 0906-AB08)
Captain Krista Pedley, Director Office of Pharmacy Affairs Health Resources and Services Administration 5600 Fishers Lane Mail Stop 08W05A Rockville, MD 20857 October 27, 2015 Re: Comments on HRSA Notice
More information340B UNIVERSITY Las Vegas Edition. May 31, 2014
340B UNIVERSITY Las Vegas Edition May 31, 2014 SESSION 1: THE TOP 5: 340B BASICS FOR HOSPITALS Mike Benedict Objectives 1. Define the intent of the 340B Program 2. Describe the major 340B stakeholders
More informationFederal 340B Drug Discount Program: Compliance Issues
Federal 340B Drug Discount Program: Compliance Issues FDLI/AHLA Conference: The Intersecting Worlds of Drug, Device, Biologics and Health Law Bill von Oehsen General Counsel, Safety Net Hospitals for Pharmaceutical
More informationToday s Agenda. Statement of Conflicts of Interest 7/9/2015
Geri Brennan Assistant Director, Health Care United States Government Accountability Office Statement of Conflicts of Interest Geri Brennan has no actual or potential conflict of interest in relation to
More informationPART B PAYMENTS FOR 340B-PURCHASED DRUGS
Department of Health and Human Services OFFICE OF INSPECTOR GENERAL PART B PAYMENTS FOR 340B-PURCHASED DRUGS Suzanne Murrin Deputy Inspector General for Evaluation and Inspections November 2015 OEI-12-14-00030
More informationImplementing a System-wide 340B Program
Implementing a System-wide 340B Program An Overview Steve Pitzer System Executive, Supply Chain Management CHRISTUS Health Sam Colletti, RPh Director of Enterprise Accounts- CHRISTUS Health Broadlane Objectives
More informationan analysis of 340B solutions a white paper by Michael J. Sovie, Pharm.D., MBA
an analysis of 340B solutions a white paper by Michael J. Sovie, Pharm.D., MBA Disclaimer Please be advised that the following information is provided for reference purposes only. This information does
More information8.310.12.1 ISSUING AGENCY: New Mexico Human Services Department (HSD). [8.310.12.1 NMAC - N, 11-1-14]
TITLE 8 SOCIAL SERVICES CHAPTER 310 HEALTH CARE PROFESSIONAL SERVICES PART 12 INDIAN HEALTH SERVICE AND TRIBAL 638 FACILITIES 8.310.12.1 ISSUING AGENCY: New Mexico Human Services Department (HSD). [8.310.12.1
More informationMedical Care Advisory Committee. Andy Vasquez, Deputy Director, Medicaid/CHIP Vendor Drug Program Health and Human Services Commission
TO: Medical Care Advisory Committee DATE: November 8, 2013 FROM: Andy Vasquez, Deputy Director, Medicaid/CHIP Vendor Drug Program Health and Human Services Commission Agenda Item No.: 7 SUBJECT: Fee-for-Service
More informationPrinted copies are for reference only. Please refer to the electronic copy of this policy for the latest version.
340B Pharmacy Audit Policy Version: 1.4 Date Created: 01/05/2015 Date Approved: 02/18/2015 Printed copies are for reference only. Please refer to the electronic copy of this policy for the latest version.
More informationStatement of the Biotechnology Industry Organization Before the Advisory Panel on Ambulatory Payment Classification Groups August 23-24, 2010
Statement of the Biotechnology Industry Organization Before the Advisory Panel on Ambulatory Payment Classification Groups August 23-24, 2010 Laurel Todd Director, Reimbursement and Health Policy Biotechnology
More informationHealth Resources Division Rule Changes (Effective 7/1/14)
Health Resources Division Rule Changes (Effective 7/1/14) Health Resources Division Mega Rule: ARM 37.85.105 The department is amending ARM 37.85.105 to reflect a 2% increase in Medicaid fees to providers.
More informationJason Mills, PharmD, MBA Pharmacy Supply Chain Manager Medical University of South Carolina
Jason Mills, PharmD, MBA Pharmacy Supply Chain Manager Medical University of South Carolina Statement of Conflicts of Interest I(Jason Mills) have no actual or potential conflict of interest in relation
More informationSECTION 5 HOSPITAL SERVICES. Free-Standing Ambulatory Surgical Center
SECTION 5 HOSPITAL SERVICES Table of Contents 1 GENERAL POLICY... 2 1-1 Clients Enrolled in a Managed Care Plan... 3 1-2 Clients NOT Enrolled in a Managed Care Plan (Fee-for-Service Clients)..................
More informationSECTION 12 - REIMBURSEMENT METHODOLOGY
SECTION 12 - REIMBURSEMENT METHODOLOGY 12.1 THE BASIS FOR ESTABLISHING A RATE OF PAYMENT...2 12.2 DETERMINING A FEE...2 12.2.A LONG-TERM CARE DISPENSING FEE REQUIREMENTS...3 12.3 MEDICARE/MEDICAID REIMBURSEMENT
More information